Ludwig scientists around the world are continually making discoveries that alter our understanding of cancer. Our science is featured in the most prestigious journals and in general media. Explore some of our most recent findings, news and reports.
For media inquiries, contact
Vice President for Communications
Ludwig researchers showcase new findings on immunotherapy, liquid biopsies and other aspects of cancer care at the 2016 Annual Meeting of the American Society of Clinical Oncology
Ludwig Cancer Research released today the full scope of Ludwig’s participation in this year’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7. Ludwig researchers will present new data and guide discussions in symposiums and poster sessions over the course of the Meeting.
“Ludwig supports the full spectrum of cancer research, from prevention to diagnosis and therapy, as well as the full range of basic biomedical science that generates new ideas for intervention in each of those areas,” said David Lane, PhD, scientific director of the Ludwig Institute for Cancer Research. “Every year, ASCO showcases Ludwig’s considerable contributions to cancer research and opens opportunities for collaboration across institutions and disciplines.”
At the Meeting, Ludwig scientists will share their expertise in areas, such as radiotherapy for cancer, HPV prevention, and diagnostic criteria in a type of lymphoma. They will also be presenting new findings and overviews on the use of DNA shed by cancer cells to diagnose cancers and monitor patients—a minimally invasive approach often referred to as liquid biopsies.
Ludwig researches will also share their expertise and contributions to cancer immunotherapy, a field that Ludwig helped to pioneer and continues to lead. Presentations will cover ongoing studies of long-term responses to combination immunotherapy for melanoma, and analyses of cellular and molecular profiles associated with various clinical responses to this therapy. They will, further, discuss efforts to develop a T cell based therapy against the NY-ESO-1 antigen, which is expressed across a number of tumor types, and the use of checkpoint blockade to treat other tumor types. This includes a description of the first phase 2 trial of checkpoint blockade using anti-PD-L1 antibodies for the treatment of the incurable brain cancer glioblastoma multiforme and a Phase 3 trial of anti-PD-1 therapy for colorectal tumors whose cells are defective in DNA repair.
Click here for a comprehensive list of Ludwig scientists’ activities at the Meeting.